Drugs by condition
Drugs approved for hodgkin lymphoma
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
15
Still marketed, NDA or BLA
Drug classes
4
Novel drugs
5
New molecular entities and new biologics
In development
36
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for hodgkin lymphoma.
- Oxderys (Doxorubicin Hydrochloride) · Avyxa Holdings Nov 9, 2026
- Gobarden (Bendamustine Hydrochloride) · Avyxa Holdings Jul 3, 2025
- Bendamustine Hydrochloride (Bendamustine Hydrochloride) · Baxter Hlthcare Corp Dec 15, 2022
- Vivimusta (Bendamustine Hydrochloride) · Azurity Dec 7, 2022
- Bendamustine Hydrochloride (Bendamustine Hydrochloride) · Apotex Dec 7, 2022
All approved drugs for hodgkin lymphoma, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 31 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Programmed Death Receptor-1 Blocking Antibody (2)
CD30-directed Immunoconjugate (1)
- Adcetris Brentuximab Vedotin · Seattle Genetics · 2011
Folate Analog Metabolic Inhibitor (1)
- Jylamvo Methotrexate · Shorla · 2022
Class not listed in FDA's data (11)
- Treanda Bendamustine Hydrochloride · Cephalon · 2008
- Matulane Procarbazine Hydrochloride · Leadiant Biosci INC · 1969
- Oxderys Doxorubicin Hydrochloride · Avyxa Holdings · 2026
- Gobarden Bendamustine Hydrochloride · Avyxa Holdings · 2025
- Bendamustine Hydrochloride Bendamustine Hydrochloride · Baxter Hlthcare Corp · 2022
- Vivimusta Bendamustine Hydrochloride · Azurity · 2022
- Bendamustine Hydrochloride Bendamustine Hydrochloride · Apotex · 2022
- Belrapzo Bendamustine Hydrochloride · Eagle Pharms · 2018
- Bendeka Bendamustine Hydrochloride · Eagle Pharms · 2015
- Doxorubicin Hydrochloride Doxorubicin Hydrochloride · Pfizer · 1987
- Methotrexate Preservative Free Methotrexate Sodium · Hospira · 1959
Drugs in development for hodgkin lymphoma
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- SurovatamigAZD0486, TNB-486Phase 39 trials
AstraZeneca · B-cell Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Untreated Follicular Lymphoma
- CC-99282BMS-986369, GolcadomidePhase 37 trials
Bristol Myers Squibb · Lymphoma, Follicular, Large B-cell Lymphoma, Non-Hodgkin Lymphoma
- OdronextamabREGN1979, OrdsponoPhase 37 trials
Regeneron · Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed/Refractory Follicular Lymphoma
- XNW5004EZH2iPhase 37 trials
Evopoint Biosciences Inc. · Relapsed/Refractory Peripheral T Cell Lymphoma, Advanced Prostate Cancer, Follicular Lymphoma, Grade 1
- TacabrutidegBGB-16673Phase 36 trials
BeOne Medicines (BeiGene) · Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma
- AbexinostatPCI-24781Phase 35 trials
Xynomic Pharmaceuticals, Inc. · Lymphoma, Follicular, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma
- KRT-232NavtemadlinPhase 34 trials
Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- CobolimabPhase 32 trials
GSK · Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma
- Rondecabtagene autoleucelLYL314Phase 32 trials
Lyell Immunopharma, Inc. · Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- GNC-038Phase 24 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-hodgkin's Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
- Relma-celCAR, CD19-targeted Chimeric Antigen Receptor T CellsPhase 23 trials
Shanghai Ming Ju Biotechnology Co., Ltd. · Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Multiple Myeloma
- Zugocabtagene geleucelCTX112Phase 23 trials
CRISPR Therapeutics AG · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy
- AB-101zabalafinPhase 22 trials
Alphyn Biologics · Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema, Atopic Dermatitis
- AK129Phase 22 trials
Akeso · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma
- AZD3470Phase 22 trials
AstraZeneca · Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- CD19 t-haNK- AdministrationPhase 22 trials
ImmunityBio, Inc. · Relapsed B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non Hodgkin Lymphoma
- AT101Anti-CD19 Chimeric Antigen Receptor T cellPhase 21 trial
AbClon · B-cell Non Hodgkin Lymphoma
- AZD4512Phase 21 trial
AstraZeneca · B-cell Non-Hodgkin Lymphoma
- BMS-986458Phase 21 trial
Bristol Myers Squibb · Relapsed/Refractory Non-Hodgkin Lymphoma
More on hodgkin lymphoma: recruiting trials · published research
Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Myelodysplastic syndromes · Myelofibrosis · Sickle cell disease · Hemophilia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.